期刊文献+

间歇性与持续性雄激素阻断治疗晚期前列腺癌疗效比较 被引量:31

Comparison of intermittent versus continuous androgen blockade in the treatment of advanced prostate cancer
原文传递
导出
摘要 目的比较间歇性与持续性雄激素阻断治疗晚期前列腺癌的疗效和副反应。方法晚期前列腺癌患者69例,分2组。A组34例行间歇性联合雄激素阻断治疗,B组35例行手术去势加抗雄激素药物即持续性雄激素阻断治疗。比较2组患者的疾病进展时间和副反应发生率。结果A组中位随访31.5(10~60)个月,B组32.6(12~63)个月。A组患者共行60个周期治疗,平均治疗周期13.7个月,其中治疗期6.4个月、间歇期7.3个月A、B组中位疾病进展时间分别为31、28个月,差异无统计学意义(P=0.446);骨转移患者中A组中位疾病进展时间24个月,B组为18个月,2组比较差异有统汁学意义(P=0.04)。2组副反应发生率分别为:潮热症状A组20.6%(7/34),B组62.9%(22/35)(P<0.01);骨质疏松A组11.8%(4/34),B组31.4%(11/35)(P< 0.05);乳房肿痛A组14.7%(5/34),B组37.1%(13/35)(P<0.05)。结论对晚期前列腺癌患者行雄激素阻断治疗应首选间歇性联合雄激素阻断治疗。 Objective To compare the efficacy and side effects of total intermittent androgen blockade (IAB) versus total continuous androgen blockade (CAB) for treating patients with advanced prostate cancer. Methods The study included 69 patients with advanced prostate cancer. Of them, 34 patients (group A) received IAB, and 35 patients (group B) underwent CAB, ie, surgical castration plus anti-androgen. The time to disease progression and side effect rate were compared between the 2 groups. Results The median follow-up period was 31.5 months (range, 10- 60 months) in group A and 32.6 months (12 -63 months) in group B. The 34 IAB-treated patients completed 60 cycles and the mean cycle length was 13.7 months (time-on treatment and time-off treatment were 6.4 months and 7.3 months, respectively). The median time to progression was 31 months in group A and 28 months in group B, respectively; there was no significant difference between groups A and B in the progression-free survival rate (P = 0. 446). But in patients with skeletal metastasis, the median time to progression was 24 months in group A and 18 months in group B, with significant difference between the 2 groups in the progression-free survival rate (P = 0.04). Side-effects were found in more patients of group B than in group A, including hot flash [62.9% (22/35) vs20.6% (7/34), P〈0.01]; osteoporosis [31.4%(11/35) vsll.8% (4/34), P〈 0.05]; gynecomastia [37.1% (13/35) vs 14.7% (5/34), P〈0.05]. Conclusions IAB is the first choice of endocrine treatment for advanced prostate cancer.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2006年第11期761-764,共4页 Chinese Journal of Urology
关键词 前列腺肿瘤 间歇性雄激素阻断 持续性雄激素阻断 去势 副反应 Prostatic neoplasms: Intermittent androgen blockade Continuous androgen blockade Castration Side effect
  • 相关文献

参考文献9

  • 1Miyamoto H,Messing EM,Chang C.Androgen deprivation therapy for prostate cancer:current status and future prospects.Prostate,2004,61:332-353. 被引量:1
  • 2Grossfeld GD,Chaudhary UB,Reese DM,et al.Intermittent androgen deprivation:update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.Urology,2001,58:240-245. 被引量:1
  • 3Cooperberg MR,Broering JM,Litwin MS,et al.The contemporary management of prostate cancer in the United States:lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE),a national disease registry.J Urol,2004,171:1393-1401. 被引量:1
  • 4Vogelzang NJ,Chodak GW,Soloway MS,et al.Goserelin versus orchiectomy in the treatment of advanced prostate cancer:final results of a randomized trial.Zoladex Prostate Study Group.Urology,1995,46:220-226. 被引量:1
  • 5Sato N,Gleave ME,Bruchovsky N,et al.Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.J Steroid Biochem Mol Bio1,1996,58:139-146. 被引量:1
  • 6de Leval J,Boca P,Yousef E,et al.Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer:results of a prospective randomized multicenter trial.Clin Prostate Cancer,2002,1:163-171. 被引量:1
  • 7Hurtado-Coll A,Goldenberg SL,Gleave ME,et al.Intermittent androgen suppression in prostate cancer:the Canadian experience.Urology,2002,60(3 Suppl 1):52-56. 被引量:1
  • 8Higano CS.Side effects of androgen deprivation therapy:monitoring and minimizing toxicity.Urology,2003,61 (2 Suppl 1):32-38. 被引量:1
  • 9Shenfeld O,Schellhammer PF.Androgen deprivation therapy.In:Lepor H,eds.Prostatic disease.Philadelphia:Saunders.2001.467-477. 被引量:1

同被引文献273

引证文献31

二级引证文献104

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部